Centessa Pharmaceuticals PLC (CNTA) reported disappointing financial results for the third quarter of fiscal 2025. The company posted an earnings per share (EPS) of $-0.41, falling short of the Wall Street consensus estimate of $-0.40 by $0.01. Revenue remained at $0.0B, matching expectations but not generating any growth.
This update provides insight into Centessa's operational performance and financial health amid potential challenges in the biotechnology sector. Investors are encouraged to review the full earnings release and tune in to the earnings conference call for further commentary on the company’s performance and outlook. Centessa Pharmaceuticals, headquartered in Altrincham, Cheshire, focuses on developing innovative therapies for neurological and neurodegenerative disorders, including its orexin receptor 2 (OX2R) agonist program.
Looking ahead, Centessa is set to report its next earnings on August 9, 2026, with EPS expectations of $-0.4641 and revenue anticipated to remain at $0.0B.